The South African government partners with Gilead Sciences to locally produce lenacapavir, a long-acting HIV prevention drug. The call for proposals, coordinated by SANAC and supported by Unitaid, USP, and MedSuRe Africa, seeks manufacturers capable of producing a WHO-quality injectable. The initiative aims to strengthen regional resilience, lower costs, and create skilled jobs.
